Neurodegenerative DiseaseiWalkNCT07285954
Mindfulness Walking Intervention to Enhance Resilience (iWalk)
A study testing iWalk Program in people with Neurodegenerative Disease and EEG, run by University of Illinois at Urbana-Champaign at 1 site in United States.
Trial summary
This study is a randomized controlled trial of the walking meditation intervention (iWalk) program, a multi-component intervention integrating walking meditation, education, and group sessions designed to enhance resilience in individuals with multiple sclerosis (MS). The objectives are to evaluate: 1. Read more about this study
- Who is it for?
- Ages 18 to 110 yearsHealthy volunteers can take part
- Conditions the study is for
- Neurodegenerative Disease, EEG, Mindfulness
- What is being tested?
- iWalk Program
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 90 participants
- Where
- 1 siteUnited States
- Study dates
- 1 Jun 2025to 31 Dec 2029
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 110 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- 18 years or older,
- clinical diagnosis of a neurodegenerative disease such as multiple sclerosis, Alzheimer's disease, Parkinson's disease, stroke, etc.,
- have not practiced meditation regularly (e.g., 10 mins per day) and have never attended any meditation classes or community programs,
- never received meditation training via coaching/certification/life coaching,
- have internet access,
- with no severe cognitive impairment, i.e., have a score of ≥ 21 on Modified Telephonic Interview for Cognitive Status (TICS-M),
Show all 12Show fewer
- be able to walk with or without an assistive device (Patient determined Disease Steps score ranged from 0-6),
- are willing to be randomized to an intervention or a control group,
- are willing to wear Fitbit (a wrist smart watch) for eight weeks,
- are individuals who are right-handed according to the Edinburgh Handedness Questionnaire,
- are willing to participate in all assessments, including in-person testing using electroencephalography (EEG) and cognitive tests, online survey/questionnaires, and online interviews or focus group discussions,
- are willing to wear a Hexoskin t-shirt, which is a heart rate variability monitor, while doing the assessments in person.
Who cannot join
- Participants who cannot speak, read, write, or listen in English.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Vaishnavi Sridharan contact
United States1 site, 1 recruiting
- Recruiting
University of Illinois Urbana-Champaign
Urbana, Illinois, 61801
Chung-Yi Chiu, 217-244-6435, chiucy@illinois.edu
chiucy@illinois.edu
About this study
Official title: A Randomized Controlled Trial of a Walking Meditation Intervention (iWalk) to Enhance Resilience in Adults
This study is a randomized controlled trial of the walking meditation intervention (iWalk) program, a multi-component intervention integrating walking meditation, education, and group sessions designed to enhance resilience in individuals with multiple sclerosis (MS).
The objectives are to evaluate:
- Recruitment capability and retention rates,
- Acceptability and adherence to the intervention,
- Feasibility of assessment procedures, and
- Preliminary effects on psychological, physiological, and behavioral outcomes.
Read the detailed description
The iWalk Program is an 8-week, multi-component behavioral intervention integrating mindfulness-based stress reduction and walking meditation to promote resilience and self-regulation in people with MS. The intervention combines weekly educational content, guided walking meditation, and group reflection delivered both in-person and virtually. Participants in the experimental group will attend three one-hour sessions per week (two via Zoom, one in-person) focusing on mindfulness, interoception, emotional regulation, and positive coping.
The waitlist control group will receive usual care during the trial period and will be offered participation after study completion.
Assessments include psychological questionnaires, electroencephalography (EEG), cognitive tasks, balance testing, and physical activity monitoring using Fitbit and Hexoskin wearable sensors. Data analysis includes assessing quantitative and qualitative changes in resilience, stress, mindfulness, mood, interoceptive awareness, quality of life, and physical activity over 8 weeks.
The total study duration is 10 weeks per participant, including baseline and post-intervention assessments.
- Conditions
- Neurodegenerative Disease, EEG, Mindfulness, Adults
- Being tested
- iWalk Program
- Keywords
- Walking meditation, Emotional regulation, EEG
- Medical subject headings
- Neurodegenerative Diseases, Emotional Regulation
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
iWalk ProgramBehavioural
A multi-component behavioral program integrating walking meditation, education, and group sessions to enhance resilience and stress regulation in adults with and without chronic conditions.
| Study group | Role | What they receive |
|---|---|---|
| iWalk Program | Active comparator | This group receives the complete iWalk program. Receives: Behavioral: iWalk Program |
| Education Only without Walking Mindfulness Practice | Active comparator | This group receives only education part of the iWalk program without walking mindfulness sessions. Receives: Behavioral: iWalk Program |
| Control Group | No intervention | This group does not receive any intervention and are placed on a waiting list. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Connor Davidson Resilience Scale for Adults (CD-RISC 25)
Measured: The baseline means assessments done two weeks before the intervention start date. Post-intervention assessments will be conducted two weeks after the intervention. Follow-up 1 is 24 weeks from baseline, and follow-up 2 is 48 weeks from baseline.
Multiple Sclerosis Resilience Scale (MSRS)
Measured: The baseline means assessments done two weeks before the intervention start date. Post-intervention assessments will be conducted two weeks after the intervention. Follow-up 1 is 24 weeks from baseline, and follow-up 2 is 48 weeks from baseline.
Stroop Task
Measured: The baseline means assessments done two weeks before the intervention start date. Post-intervention assessments will be conducted two weeks after the intervention. Follow-up 1 is 24 weeks from baseline, and follow-up 2 is 48 weeks from baseline.
Symbol Digit Modalities Test
Measured: The baseline means assessments done two weeks before the intervention start date. Post-intervention assessments will be conducted two weeks after the intervention. Follow-up 1 is 24 weeks from baseline, and follow-up 2 is 48 weeks from baseline.
Wisconsin Card Sorting Test
Measured: The baseline means assessments done two weeks before the intervention start date. Post-intervention assessments will be conducted two weeks after the intervention. Follow-up 1 is 24 weeks from baseline, and follow-up 2 is 48 weeks from baseline.
Sustained Attention to Response Task
Measured: The baseline means assessments done two weeks before the intervention start date. Post-intervention assessments will be conducted two weeks after the intervention. Follow-up 1 is 24 weeks from baseline, and follow-up 2 is 48 weeks from baseline.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Dec 2025
- Study start1 Jun 2025
- Primary completion31 Dec 2029 (estimated)
- Study completion31 Dec 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Neurodegenerative DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 90 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Illinois at Urbana-Champaign
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Chung-Yi Chiu, University of Illinois at Urbana-Champaign
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07285954
- Sponsor's protocol ID
- IRB25-0202
- Acronym
- iWalk
- Status last verified
- Dec 2025
- First submitted
- 16 Oct 2025
- Last updated
- 16 Dec 2025
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 16 Dec 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomized Controlled Trial of a Walking Meditation Intervention (iWalk) to Enhance Resilience in Adults
- ClinicalTrials.gov ID
- NCT07285954
- Acronym / sponsor ID
- iWalk / IRB25-0202
- Conditions
- Neurodegenerative Disease, EEG, Mindfulness, Adults
- Keywords
- Walking meditation, Emotional regulation, EEG
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 90 participants (estimated)
- Lead sponsor
- University of Illinois at Urbana-ChampaignUniversity, hospital or other
- Study start
- 1 Jun 2025 (actual)
- Primary completion
- 31 Dec 2029 (estimated)
- Study completion
- 31 Dec 2029 (estimated)
- First posted
- 16 Dec 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study is a randomized controlled trial of the walking meditation intervention (iWalk) program, a multi-component intervention integrating walking meditation, education, and group sessions designed to enhance resilience in individuals with multiple sclerosis (MS).
The objectives are to evaluate:
- Recruitment capability and retention rates,
- Acceptability and adherence to the intervention,
- Feasibility of assessment procedures, and
- Preliminary effects on psychological, physiological, and behavioral outcomes.
Detailed description
The iWalk Program is an 8-week, multi-component behavioral intervention integrating mindfulness-based stress reduction and walking meditation to promote resilience and self-regulation in people with MS. The intervention combines weekly educational content, guided walking meditation, and group reflection delivered both in-person and virtually. Participants in the experimental group will attend three one-hour sessions per week (two via Zoom, one in-person) focusing on mindfulness, interoception, emotional regulation, and positive coping.
The waitlist control group will receive usual care during the trial period and will be offered participation after study completion.
Assessments include psychological questionnaires, electroencephalography (EEG), cognitive tasks, balance testing, and physical activity monitoring using Fitbit and Hexoskin wearable sensors. Data analysis includes assessing quantitative and qualitative changes in resilience, stress, mindfulness, mood, interoceptive awareness, quality of life, and physical activity over 8 weeks.
The total study duration is 10 weeks per participant, including baseline and post-intervention assessments.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| iWalk Program | Active comparator | Behavioral: iWalk ProgramThis group receives the complete iWalk program. |
| Education Only without Walking Mindfulness Practice | Active comparator | Behavioral: iWalk ProgramThis group receives only education part of the iWalk program without walking mindfulness sessions. |
| Control Group | No intervention | –This group does not receive any intervention and are placed on a waiting list. |
Who may qualify
- Ages
- 18 to 110 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (12 listed)
- 18 years or older,
- clinical diagnosis of a neurodegenerative disease such as multiple sclerosis, Alzheimer's disease, Parkinson's disease, stroke, etc.,
- have not practiced meditation regularly (e.g., 10 mins per day) and have never attended any meditation classes or community programs,
- never received meditation training via coaching/certification/life coaching,
- have internet access,
Key exclusion criteria (1 listed)
- Participants who cannot speak, read, write, or listen in English.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| iWalk ProgramA multi-component behavioral program integrating walking meditation, education, and group sessions to enhance resilience and stress regulation in adults with and without chronic conditions. | Behavioural | Education Only without Walking Mindfulness Practice, iWalk Program |
Primary outcome
Connor Davidson Resilience Scale for Adults (CD-RISC 25)
Time frame: The baseline means assessments done two weeks before the intervention start date. Post-intervention assessments will be conducted two weeks after the intervention. Follow-up 1 is 24 weeks from baseline, and follow-up 2 is 48 weeks from baseline.
Multiple Sclerosis Resilience Scale (MSRS)
Time frame: The baseline means assessments done two weeks before the intervention start date. Post-intervention assessments will be conducted two weeks after the intervention. Follow-up 1 is 24 weeks from baseline, and follow-up 2 is 48 weeks from baseline.
Stroop Task
Time frame: The baseline means assessments done two weeks before the intervention start date. Post-intervention assessments will be conducted two weeks after the intervention. Follow-up 1 is 24 weeks from baseline, and follow-up 2 is 48 weeks from baseline.
Symbol Digit Modalities Test
Time frame: The baseline means assessments done two weeks before the intervention start date. Post-intervention assessments will be conducted two weeks after the intervention. Follow-up 1 is 24 weeks from baseline, and follow-up 2 is 48 weeks from baseline.
Wisconsin Card Sorting Test
Time frame: The baseline means assessments done two weeks before the intervention start date. Post-intervention assessments will be conducted two weeks after the intervention. Follow-up 1 is 24 weeks from baseline, and follow-up 2 is 48 weeks from baseline.
Sustained Attention to Response Task
Time frame: The baseline means assessments done two weeks before the intervention start date. Post-intervention assessments will be conducted two weeks after the intervention. Follow-up 1 is 24 weeks from baseline, and follow-up 2 is 48 weeks from baseline.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Dec 2025.
- Individual participant dataSharing planned: No
Related trials for Neurodegenerative Disease
Active, not recruitingPhase 2
Effect of Equol Supplementation on Arterial Stiffness and Cognition in Healthy Volunteers
Arterial Stiffness, White Matter Lesions
RecruitingObservational study
Investigating Complex Neurodegenerative Disorders Related to Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
Frontotemporal Dementia, Amyotrophic Lateral Sclerosis
Not yet recruiting
Comparative Effects of Virtual Reality and Proprioceptive Neuromuscular Facilitation in Patients With Parkinson's Disease
Parkinson Disease
Active, not recruiting
Myrosinase Bioactivated Gglucoraphanin for the Treatment of Neurodegenerative Diseases (GRA-MYR-ND)
PARKINSON DISEASE (Disorder), Multiple Sclerosis (MS) - Relapsing-remitting
Active, not recruiting
Efficacy of Stabilometric Platform to Improve Standing Balance in Patients With Friedreich's Ataxia
Friedreich Ataxia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Vaishnavi Sridharan contact
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing iWalk Program in people with Neurodegenerative Disease and EEG, run by University of Illinois at Urbana-Champaign at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 12 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 16 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Chung-Yi Chiu (12172446435, chiucy@illinois.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Connor Davidson Resilience Scale for Adults (CD-RISC 25) (time frame: The baseline means assessments done two weeks before the intervention start date. Post-intervention assessments will be conducted two weeks after the intervention. Follow-up 1 is 24 weeks from baseline, and follow-up 2 is 48 weeks from baseline.). The study lists 6 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Dec 2025.